에 대한 최신 뉴스 BILL Holdings (NYSE:BILL) 주식

BILL HOLDINGS INC

BILL Holdings

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Bill.com Holdings

benzingaai2023_modern_computer_screen_with_stock_chart_stock__6576dd35-b4b0-42d8-8403-ba4e9845ab24_3

News

Hedge Funds

Trading Ideas

BILL

CFLT

CRMD

ICLR

MSTR

NVDA

RING

WOLF

엘리엇 인베스트먼트 매니지먼트는 4분기 동안 여러 포트폴리오 조정을 하였다. 여러 옵션 포지션을 청산하고 이 행동주의 투자 회사의 기술 노출을 재편했다. 미국 증권 거래 위원회에 제출된 새로운 13-F 파일링에 따르면, 엘리엇은 4분기에 다음과 같은 새로운 포지션을 추가했다:

엘리엇 인베스트먼트가 울프스피드 주식을 매수하고 4분기에는 엔비디아 풋 옵션에 베팅

Young,Indian,Businessman,Holding,Phone,Reading,Bank,Receipt,Calculating,Taxes,

Earnings Beats

Long Ideas

Options

Movers

겉보기에는 결제 처리 전문 회사인 빌 홀딩스(빌닷컴)(NYSE:BILL)이 지난주처럼 폭락할 이유가 없어 보였다. 목요일, 이 회사는 2023 회계년도 2분기 재무 결과를 발표하며 3억 6,255만 달러의 매출과 주당 56센트의 조정된 순이익을 기록했다. 이 수치는 각각 3억 6,023만 달러와 46센트라는 애널리스트들의 컨센서스 예상치를 모두 초과한 결과이다. 그럼에도 불구하고 빌닷컴의 주식은 실적 결과 발표 후 급락했다.

옵션 코너: 빌 홀딩스의 실적 후 폭락으로 투기자들에게 할인된 매수 거래 기회 제공

benzingaai2023_stock_market_charts_on_multiple_computer_scree_03ada781-be05-460b-a6af-38988bc7658b_1

Earnings

Guidance

After-Hours Center

빌 홀딩스(NYSE:BILL)는 목요일(6일) 2분기 재무 실적을 발표한 후 주가가 시간외 거래에서 급락했다. 실적 보고서 요약은 다음과 같다.

빌 홀딩스, 2분기 실적 발표 이후 주가 29% 급락한 이유는?

BILL Holdings Inc

BILL IDENTITY LTD by BILL IDENTITY LTD

Billerud AB

BillionHappiness

Market analysts say President Donald Trump's newly announced global tariff regime is already reshaping investor sentiment, triggering sharp corrections <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44625640/anthony-pompliano-praises-trumps-tariffs-as-catalyst-for-crypto-innovation">across risk assets—including crypto. </a>
While digital currencies initially showed some resilience, experts caution that they remain exposed to broader macroeconomic shocks.
Trump's April 2 speech, which introduced a "reciprocal tariff" program with baseline rates starting at 10% and scaling up to 50% by April 9, caused immediate <a href="https://www.benzinga.com/25/04/44622346/trumps-reciprocal-tariff-math-a-masterclass-in-economic-absurdity">volatility in financial markets</a>.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has dipped below $82,000, while U.S. equity futures and global ETFs slid.
Trump described the move as a "Declaration of Economic Independence," aimed at rebalancing global trade dynamics.
According to David Hernandez, a crypto investment specialist at 21Shares, the tariffs removed some ambiguity around U.S. trade policy but raised new concerns. 
"Markets thrive on clarity, and now that the scope is known, we may see institutions buy the dip," he said. "Still, the announcement rattled equities and crypto alike. Bitcoin held above key support at $82,000 but couldn't avoid broader risk-off pressure."
James Toledano, COO at Unity Wallet, observed that crypto wasn't immune to the impact. 
"Bitcoin is down 4.9% on the week, holding around $82,000," he said. "This shows that in the early stages of global instability, digital assets behave more like tech stocks than safe havens."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44628685/bitcoin-is-a-realistic-global-reserve-asset-experts-say">Bitcoin Is A Realistic Global Reserve Asset, Experts Say</a>
Toledano added that if the situation escalates into a prolonged economic standoff, crypto could gain renewed appeal. "We're not at safe haven status yet, but if confidence in fiat wavers, Bitcoin might decouple over time."
Javier Rodriguez-Alarcon, Chief Commercial Officer at XBTO, echoed that view, noting the correlation between Bitcoin and traditional markets during moments of high volatility. "Bitcoin still trades like a risk asset during policy shocks. That doesn't negate its long-term potential, but the narrative as a hedge is still maturing."
He added that as digital assets gain wider institutional traction, future dislocations may see crypto react differently. 
For now, however, "the sell-off shows crypto is still subject to the same sentiment-driven dynamics that move traditional finance."
Despite these headwinds, Hernandez noted that institutional inflows into Bitcoin ETFs remained steady, suggesting some investors may view the dip as an entry point. 
"The market reaction underscores Bitcoin's borderless appeal in hedging against geopolitical uncertainty," he said.
With key U.S. trading partners expected to respond in the coming days, including China, South Korea, and Mexico, analysts say further volatility is likely across all asset classes—crypto included.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44627407/gold-overtaking-bitcoin-in-inflation-hedge-strategy-jpmorgan-says">Gold Overtaking Bitcoin In Inflation Hedge Strategy, JPMorgan Says</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin As Trump Tariff Safe Haven? Not Yet, But 'Might Decouple Over Time,' Expert Says

Dutch advanced chipmaking equipment supplier ASML Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) plans to quintuple its Japan-based maintenance staff for the machines in the next few years, Nikkei <a target="_blank" href="https://asia.nikkei.com/Business/Tech/Semiconductors/ASML-to-quintuple-advanced-EUV-chip-tools-staff-in-Japan" rel="noreferrer noopener">reported</a> Tuesday.
ASML manufactures extreme ultraviolet (EUV) lithography equipment for making advanced technology chips.
In December, Rapidus became the first Japanese chipmaker to receive EUV machines.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china" rel="noreferrer noopener">Huawei Boosts AI Chip Production Despite Taiwan Semi And ASML Ban, Aims to Challenge Nvidia In China</a>
Japan continues bolstering its advanced semiconductor technology position, as in the U.S., Europe, and China.
Japanese multinational investment holding company Softbank Group Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) is <a target="_blank" href="https://www.benzinga.com/media/25/04/44589685/softbank-weighs-165-billion-loan-that-could-back-openais-40-billion-raise-report" rel="noreferrer noopener">weighing a loan</a> of up to $16.5 billion to finance its&nbsp;U.S. artificial intelligence ambitions. The loan may help SoftBank lead a $40 billion&nbsp;funding round&nbsp;in OpenAI. The move values the ChatGPT parent&nbsp;at $300 billion.
Contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is expanding globally with <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42843001/taiwan-semiconductor-ramps-up-production-in-japan-us-and-germany-to-diversify-away-from-china" rel="noreferrer noopener">plants in the U.S., Japan, and Germany</a>.
Meanwhile, ASML continues to gain traction, which is backed by the higher demand for semiconductor chips.
In March, ASML and imec forged a <a target="_blank" href="https://www.benzinga.com/markets/eurozone/25/03/44253751/asml-boosts-ai-chip-rd-in-europe-amid-us-sanctions-china-slowdown-and-subsidy-uncertainty" rel="noreferrer noopener">five-year deal</a> complemented by funding made available by the Chips Joint Undertaking, the Flemish government, and&nbsp;the Dutch government to boost semiconductor R&amp;D and sustainable innovation with EU and government backing to develop sub-2nm chips and advance AI-ready semiconductor solutions.
ASML Holding stock has plunged 34% in the last 12 months. The company disclosed in its&nbsp;annual report that the U.S. semiconductor sanctions on China hurt 2024 demand, with China making up 36% of its sales.
ASML customers slashed capital spending amid U.S. chip restrictions, impacting AI and semiconductor growth. Additionally, reports indicated President Donald Trump&#8217;s plans to scrap&nbsp;the U.S. CHIPS Act.
The EUV lithography market size was worth $10.09 billion in 2023 and is <a target="_blank" href="https://www.globenewswire.com/news-release/2025/03/21/3047088/0/en/Extreme-Ultraviolet-EUV-Lithography-Market-to-Hit-USD-35-70-billion-by-2032-Driven-by-Rising-Demand-for-Advanced-Semiconductor-Manufacturing-SNS-Insider.html" rel="noreferrer noopener">expected to reach</a> $35.70 Billion by 2032 and grow at a CAGR of 15.1% over the forecast period 2024-2032.
The growth potential reflects technological advancements, increasing semiconductor complexity, and the demand for smaller, more powerful chips. Industries like AI, high-performance computing, 5G, and IoT.
Price Action:&nbsp;ASML stock is down 4.55% at $638.55 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43938789/intel-deploys-asmls-advanced-euv-machines-aims-to-challenge-taiwan-semiconductors-lead" target="_blank" rel="noreferrer noopener">Intel Deploys ASML&#8217;s Advanced EUV Machines, Aims to Challenge Taiwan Semiconductor&#8217;s Lead</a></li>
</ul>
Photo via Shutterstock

Asia

Tech

Media

ASML

SFTBF

SFTBY

Chip Equipment Maker ASML To Boost Japan Workforce 5x Amid Global Race For Advanced Semiconductor Tech

OTIS

Live On CNBC: Josh Brown Buys OTIS

KinderCare Learning Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) is under fire Thursday following a <a href="https://thebearcave.substack.com/p/problems-at-kindercare-learning-companies">new report</a> from The Bear Cave, which alleges safety failures, regulatory concerns and a deteriorating reputation at the nation's <a href="https://www.benzinga.com/quote/KLC">largest private childcare provider</a>.
What Happened: The Bear Cave released a short report on KinderCare Thursday, alleging the company is plagued by operational failures that could threaten its stock performance.
"Recent investigations reveal alarming safety incidents, including children left unsupervised, instances of abuse and regulatory violations that raise serious concerns about KinderCare's ability to operate responsibly," the short seller said.
Benzinga has reached out to KinderCare Learnings Companies for comment on the report.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44629335/apple-stock-slammed-by-trump-tariffs-is-a-death-cross-next">Apple Stock Slammed By Trump Tariffs: Is A Death Cross Next?</a>
KinderCare operates roughly 1,500 childcare centers across 41 states and relies heavily on government funding. The company went public in 2022, positioning itself as a leader in early childhood education.
The Bear Cave&#8217;s report cites troubling incidents, including a <a href="https://www.jsonline.com/story/communities/south/2024/11/20/cudahy-woman-pleads-guilty-in-oak-creek-kindercare-cocaine-case/76434101007/">case</a> where an 11-month-old tested positive for cocaine at a KinderCare center in Wisconsin. Other reports detail children <a href="https://wcti12.com/news/local/teachers-on-leave-after-toddler-wanders-onto-busy-road-from-daycare">escaping</a> facilities, being <a href="https://www.nbcnews.com/news/us-news/florida-mom-finds-toddler-locked-day-care-workers-left-day-rcna16918">locked</a> inside after closing hours and experiencing mistreatment by staff.
&#8220;In sum, The Bear Cave believes KinderCare is a broken business that harms the children and families it claims to help,&#8221; the short seller said.
The Bear Cave reported that KinderCare has faced repeated scrutiny from regulatory agencies. The short seller believes growing concerns could impact its ability to secure funding and expand operations.
The short seller also highlighted online complaints from parents and former employees, with some alleging understaffing, inadequate training and neglect.
KLC Price Action: <a href="http://benzinga.com/quote/klc">KinderCare shares</a> are falling by 10.8 % during Thursday&#8217;s session, trading at $11.40 at the time of publication. According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, KinderCare has a 52-week high of $29.89 and a 52-week low of $10.91 after making new lows for the year in Thursday&#8217;s session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely" target="_blank" rel="noreferrer noopener">Trump's Tariffs Prompt China To Vow ‘Countermeasures': Experts See Retaliation Likely</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/lordn">Lordn</a>/Shutterstock.

Short Sellers

Short Ideas

Short Seller Slams KinderCare Over Safety Failures, Stock Hits New 52-Week Low

WIIM

ACDC

CGBS

CIVI

EQNR

FANG

SHEL

Shares of energy companies are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Truist Securities analyst William Stein maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Hold and lowers the price target from $373 to $280.

Price Target

Analyst Ratings

TSLA

Truist Securities Maintains Hold on Tesla, Lowers Price Target to $280

TIVC

Tivic Health Shares resume Trading

Tivic Health Shares Halted On Circuit Breaker To Downside; Stock Up 53.9%

Genius Group Ltd (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares are trading lower on Thursday following news that the company is being compelled <a href="https://www.benzinga.com/pressreleases/25/04/g44625455/genius-group-blocked-from-raising-funds-and-buying-bitcoin-by-new-york-court" target="_blank" rel="noreferrer noopener">to sell its Bitcoin treasury.</a>
The move comes after a court ruling in the U.S. District Court Southern District of New York, which blocked Genius from selling shares, raising funds and using investor money to purchase Bitcoin.
This injunction was granted as part of a larger legal battle with Fatbrain AI, part of Lzg International Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZGI#OTC">LZGI</a>), where Genius had initiated arbitration to terminate its asset purchase agreement with the company.
The court&#8217;s decision is based on fraud allegations against LZGI executives Michael Moe and Peter Ritz, who have been accused of defrauding shareholders.
Also Read: <a target="_blank" href="https://www.benzinga.com/top-stories/25/04/44627817/retaliation-odds-spike-after-trumps-heavy-tariffs-sending-country-etfs-tumbling" rel="noreferrer noopener">Retaliation Odds Spike After Trump&#8217;s Heavy Tariffs, Sending Country ETFs Tumbling</a>
Genius filed motions and presented evidence of what it claims is a scheme to extort money from the company through the legal process.
As a result, Genius&#8217;s ability to finance its operations and issue share compensation to employees has been blocked, forcing the company to consider drastic measures.
In response, Genius is actively appealing the injunction, while restructuring its operations, including downsizing and halting marketing and investment activities.
The company has been forced to sell some of its Bitcoin holdings to sustain operations, reducing its treasury from 440 Bitcoin to 430 Bitcoin.
Despite the challenges, CEO Roger James Hamilton remains committed to fighting fraud and market manipulation and intends to protect shareholders&#8217; interests.
The ongoing restrictions, however, pose a serious risk to the company's future operations, with Genius&#8217; stock price falling 53% since the temporary restraining order was imposed.
GNS Price Action: Genius shares are trading lower by 11.88% to 22 cents at publication Thursday.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/25/04/44624245/tariffs-to-plug-the-hole-for-income-tax-cuts-to-come-economists-predict-what-more-could-be-expected" target="_blank" rel="noreferrer noopener">Trump Tariffs To ‘Plug The Hole' For Income Tax Cuts To Come: Economists Predict What More Could Be Expected</a></li>
</ul>
Photo: Courtesy Genius Group

Legal

Markets

General

LZGI

What's Going On With Genius Group Stock Today?

CART

CASY

CELH

CHEF

COST

HNST

PFGC

USFD

Shares of companies within the broader consumer staples sector are trading lower as markets react to President Trump's announcement of sweeping tariffs.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 800 points on Thursday.
The Dow traded down 3.07% to 40,929.87 while the NASDAQ fell 4.83% to 16,750.33. The S&amp;P 500 also fell, dropping, 3.73% to 5,459.39.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44625270/top-3-tech-and-telecom-stocks-youll-regret-missing-this-month">Top 3 Tech And Telecom Stocks You&#8217;ll Regret Missing This Month</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.4% on Thursday.
In trading on Thursday, energy shares tumbled by 5.6%.
Top Headline
The ISM services PMI dipped to 50.8 in March versus a reading of 53.5 in February, and down from market estimates of 53.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares shot up 10% to $59.60 after the company reported better-than-expected third-quarter financial results and issued FY25 sales guidance above estimates.</li>
<li>Shares of NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>)got a boost, surging 95% to $1.15 after the company announced it secured $5.2 million in funding to drive international expansion.</li>
<li>The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) shares were also up, gaining 12% to $10.19.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Aldeyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares dropped 76% to $1.2750 after the company received a response letter from the FDA for the Reproxalap new drug application for the treatment of signs and symptoms of dry eye disease.</li>
<li>Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) were down 41% to $147.59 after the company reported weaker-than-expected fourth-quarter financial results.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) was down, falling 22% to $26.30. Shares of specialty retailers in the furniture and home goods space traded lower following disappointing earnings from RH.</li>
</ul>
Commodities In commodity news, oil traded down 7.1% to $66.64 while gold traded down 1.8% at $3,110.80.
Silver traded down 7.1% to $32.205 on Thursday, while copper fell 3.4% to $4.8705.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 2.19%, Germany's DAX 40 dipped 2.11% and France's CAC 40 fell 2.93%. Spain's IBEX 35 Index fell 1.32%, while London's FTSE 100 fell 1.30%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 dipping 2.77%, China's Shanghai Composite Index falling 0.24%, Hong Kong's Hang Seng Index falling 1.52% and India's BSE Sensex falling 0.42%.
Economics
<ul>
<li>U.S. initial jobless claims fell by 6,000 to 219,000 in the week ending March 29, compared to market estimates of 225,000.</li>
<li>The U.S. trade deficit shrank to $122.7 billion in February compared to $130.7 billion in the previous month and versus market estimates of a $123.5 billion gap.</li>
<li>The S&amp;P Global services PMI was revised higher to 54.4 in March compared to a preliminary reading of 54.3.</li>
<li>The S&amp;P Global composite PMI climbed to 53.5 in March versus 51.6 in the previous month.</li>
<li>The ISM services PMI dipped to 50.8 in March versus a reading of 53.5 in February, and down from market estimates of 53.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

ALDX

NIVF

Crude Oil Dips 7%; ISM Services PMI Falls In March

Macro Economic Events

Econ #s

Economics

Canada PM Carney Says: He May Speak With Trump Again But Nothing Scheduled

PAAS

Shares of precious metals stocks are trading lower as markets react to President Trump's announcement of sweeping tariffs.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">rapid disease progression</a>.
Vanrafia is a once-daily, non-steroidal, oral treatment that can be added to supportive care, including a renin-angiotensin system inhibitor with or without a sodium-glucose co-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44619827/novartis-receives-fda-accelerated-approval-for-vanrafia-atrasentan-the-first-and-only-selective-en" rel="noreferrer noopener">transporter-2 inhibitor</a>.
Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase 3 ALIGN study measuring the reduction of proteinuria at 36 weeks compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44592342/apellis-pharmaceuticals-rare-kidney-disease-drug-under-fda-review-seeks-to-compete-novartis-recently-approved-drug" rel="noreferrer noopener">FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals</a>
It has not been established whether Vanrafia slows kidney function decline in patients with IgAN.
The continued approval of Vanrafia may be contingent upon verifying clinical benefit from the ongoing Phase 3 ALIGN study evaluating whether Vanrafia slows disease progression as measured by estimated glomerular filtration rate (eGFR) decline at week 136.
The eGFR data are expected in 2026 and are intended to support traditional FDA approval.
In the ongoing Phase 3 ALIGN study, patients receiving Vanrafia in combination with a RAS inhibitor achieved clinically meaningful and statistically significant proteinuria reduction of 36.1% compared to placebo, with results seen as early as week 6 and sustained through week 36.
A similar treatment effect of Vanrafia was seen in an additional group of patients treated with both an RAS inhibitor and an SGLT2 inhibitor (37.4% reduction in UPCR vs. placebo).
The ALIGN study showed that Vanrafia has a favorable safety profile consistent with previously reported data.
This is Novartis&#8217;s third U.S. approval for its kidney disease portfolio in the last year. Fabhalta&nbsp;was granted FDA approval in <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44544720/fda-oks-novartis-prostate-cancer-treatment-triples-eligible-patient-pool" rel="noreferrer noopener">C3 glomerulopathy in&nbsp;March 2025</a> and accelerated approval in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40254535/fda-approves-expanded-use-of-novartis-rare-disease-drug-fabhalta-for-kidney-disease" rel="noreferrer noopener">IgAN in&nbsp;August 2024</a>.
Fabhalta is also being studied in rare kidney diseases, including atypical hemolytic uremic syndrome, immune complex membranoproliferative glomerulonephritis, and lupus nephritis.
An investigational subcutaneously administered anti-APRIL monoclonal antibody, zigakibart, is currently in Phase 3 development in IgAN, with results expected in 2026.
Price Action: NVS stock is up 2.16% at $113.17 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44614171/uks-health-agency-endorses-pfizers-blood-cancer-combo-therapy-as-first-for-untreated-hodgkin-lymphoma-patients" target="_blank" rel="noreferrer noopener">UK&#8217;s Health Agency Endorses Pfizer&#8217;s Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients</a></li>
</ul>
Photo by Taljat David via Shutterstock

Biotech

Health Care

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

The <a href="https://www.benzinga.com/topic/u-s-food-and-drug-administration">U.S. Food and Drug Administration</a> (FDA) on Thursday granted orphan drug designation to Sanofi SA&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) rilzabrutinib.
The treatment is an investigational, novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">IgG4-related disease (IgG4-RD)</a>.
The FDA grants orphan drug designation to investigational therapies that address rare medical diseases or conditions that affect fewer than 200,000 people in the US.
Rilzabrutinib is <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-03-05-00-00-3054815" rel="noreferrer noopener">currently</a> under regulatory review in the US, the EU, and China for its potential use in immune thrombocytopenia (ITP).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" rel="noreferrer noopener">Pharmaceutical Firms Say UK Investment Is &#8216;Unlikely&#8217; Unless Payment Levy Is Addressed</a>
The target action date for the FDA regulatory decision on ITP, which was granted fast-track designation, is Aug. 29.
Rilzabrutinib also received orphan drug designation for ITP in the US, EU, and Japan.
Results from a phase 2b study on wAIHA&nbsp;presented at ASH 2024 demonstrated that treatment with rilzabrutinib showed clinically meaningful outcomes on response rate and disease markers.
In IgG4-RD patients, results from a phase 2a study showed treatment with rilzabrutinib for 52 weeks led to reduction in disease flare, other disease markers, and glucocorticoid sparing.
The safety profile of rilzabrutinib in both studies was consistent with previous studies.
Last week, the FDA approved&nbsp;Sanofi&#8217;s Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44560065/fda-approves-sanofis-hemophilia-drug" rel="noreferrer noopener">factor VIII or IX inhibitors</a>.
The&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-28-20-07-38-3051637" rel="noreferrer noopener">approval</a>&nbsp;is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates.
Price Action: Sanofi&#8217;s stock is up 3.54% at $55.86 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44613863/biomarin-seeks-label-expansion-for-palynziq-after-positive-phase-3-results-in-adolescent-patients" target="_blank" rel="noreferrer noopener">BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients</a></li>
</ul>
Image: Shutterstock

Large Cap

Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?

ASPI

CENX

FEAM

MATV

MEOH

MERC

PACK

TECK

VALE

Shares of companies within the broader materials sector are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Canada PM Carney Says: Call With Trump Helped Canada Avoid Reciprocal Tariffs

TD Securities analyst Craig Hutchison maintains Trilogy Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TMQ#TSX">TMQ</a>) with a Hold and raises the price target from C$2 to C$2.25.

TSX:TMQ

TD Securities Maintains Hold on Trilogy Metals, Raises Price Target to C$2.25

<a href="https://investor.gm.com/news-releases/news-release-details/gm-reports-strong-q1-china-growth-evs-and-hybrids" title="https://investor.gm.com/news-releases/news-release-details/gm-reports-strong-q1-china-growth-evs-and-hybrids">https://investor.gm.com/news-releases/news-release-details/gm-reports-strong-q1-china-growth-evs-and-hybrids</a>

General Motors And Its Joint Ventures Announces It Delivered More Than 442,000 Units In China In Q1 2025

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) just pulled back the curtain on its cloud ambitions at OCI Day, giving investors a close-up look at <a href="https://www.benzinga.com/topic/artificial-intelligence">its AI-powered</a> data center expansion.
While AI demand continues to surge, JPMorgan analyst Mark R. Murphy remains cautious, maintaining a Neutral stance on Oracle stock with a $135 price target, below its current trading level of $145.86.
<h1 class="wp-block-heading">AI Demand: Booming, But Is It Enough?</h1>
Oracle is doubling down on its AI infrastructure, expanding its customer-facing regions from 69 to 101 in the past year. But while the company insists demand is outpacing supply, Murphy notes that this messaging feels less urgent than before. 
Still, Oracle's investment in AI data centers suggests confidence in sustained demand, despite growing chatter about an "overbuild" or even an AI bubble.
Read Also: <a href="https://www.benzinga.com/news/25/04/44613084/amazon-makes-surprise-bid-for-tiktok-amid-us-ban-threat-report">Amazon&#8217;s Surprise Bid For TikTok As U.S. Ban Threat Looms</a>
<h1 class="wp-block-heading">Training Vs. Inferencing: Oracle Sees No Difference</h1>
One of the most debated topics in AI infrastructure is the difference between training (building models) and inferencing (running models). While Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) leans heavily on inferencing for steady revenue, Oracle argues that for major customers, both processes look the same. This implies a more persistent AI compute need than skeptics might believe, said Murphy.
<h1 class="wp-block-heading">Bubble Concerns? Oracle Hedging Its Bets</h1>
With Microsoft CEO Satya Nadella warning of an AI "overbuild" and Alibaba Group Holdings Ltd's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) chairman hinting at a potential bubble, Oracle's response was refreshingly pragmatic, Murphy noted.
Oracle Executive Vice President Clay Magouyrk dodged long-term predictions, instead emphasizing infrastructure flexibility — stating Oracle could repurpose its GPUs for general computing or storage if AI demand wanes. This adaptability could prove crucial if the AI hype cycle falters.
<h1 class="wp-block-heading">Oracle's Data Center Push: Big, But Not The Biggest</h1>
The event took place at Oracle's Novva facility in Utah, a massive operation but one dwarfed by neighboring Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) data centers.
Oracle also showcased plans for an even larger facility in Abilene, Texas, suggesting its AI cloud ambitions are just getting started.
Murphy sees Oracle's AI-driven cloud expansion as a long-term play, but acknowledges near-term challenges — particularly hefty capital expenditures cutting into free cash flow.
While Oracle's growth trajectory is promising, it still faces hurdles in keeping up with hyperscaler giants. For now, the AI gold rush continues — but not without risks.
ORCL Price Action: Oracle stock is down 5.41% at $137.97 Thursday morning at publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44601400/nvidia-rival-amd-completes-4-9b-acquisition-of-zt-systems-to-strengthen-ai-and-data-center-dominance">Nvidia Rival AMD Completes $4.9B Acquisition Of ZT Systems To Strengthen AI And Data Center Dominance</a></li>
</ul>
Photo: Shutterstock

Analyst Color

AMZN

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

MSFT

ORCL

Oracle's AI Bet: Overbuilt Or Future-Proof? Analyst Weighs In

Press Releases

BILL to Participate in Upcoming Investor Conference

BILL to Offer $1.0 Billion of Convertible Senior Notes due 2030

BILL Announces Pricing of Upsized Offering of $1.25 Billion of 0% Convertible Senior Notes Due 2030

BILL Announces Closing of Offering of $1.4 Billion of 0% Convertible Senior Notes due 2030, Including Full Exercise of Initial Purchasers' $150.0 Million Option to Purchase Additional Notes

BILL Unveils 1099 Form Filing Solution for SMBs

Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

Industry Leaders Keri Gohman and Dan Wernikoff Join BILL Board of Directors

BILL to Report Fiscal Second Quarter 2025 Results

BILL Reports Second Quarter Fiscal Year 2025 Financial Results

CTLT

SPGI

ACI Worldwide

AppFolio

Asana

AvePoint

BlackLine

Blackbaud

Braze

CCC Intelligent Solutions Holdings Inc. - Common Stock

CCC Intelligent Solutions

Confluent

Clearwater Analytics Holdings, Inc. Class A Common Stock

Clearwater Analytics Hldg

Dropbox

Freshworks

InterDigital

Informatica

Intapp

Life360

MARA Holdings

Pegasystems

Q2 Holdings

SoundHound AI, Inc. - Class A Common Stock

SoundHound AI

SPS Commerce

Vertex

Workiva

Zeta Global Holdings Corp. Class A Common Stock

Zeta Global Holdings

Goldman Sachs

Keefe, Bruyette & Woods

Keybanc

Needham

Oppenheimer

엘리엇 인베스트먼트 매니지먼트는 4분기 동안 여러 포트폴리오 조정을 하였다. 여러 옵션 포지션을 청산하고 이 행동주의 투자 회사의 <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">기술 노출</a>을 재편했다.
미국 증권 거래 위원회에 제출된 새로운 <a href="https://www.sec.gov/Archives/edgar/data/1791786/000101359425000294/xslForm13F_X02/primary_doc.xml" target="_blank" rel="noreferrer noopener">13-F</a> 파일링에 따르면, 엘리엇은 4분기에 다음과 같은 새로운 포지션을 추가했다:
<ul>
<li>울프스피드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>)</li>
</ul>
<ul>
<li>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 풋 옵션</li>
</ul>
<ul>
<li>SPDR Select Sector Fund Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) 풋 옵션</li>
</ul>
<ul>
<li>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) 풋 옵션</li>
</ul>
다음은 엘리엇이 4분기에 추가한 모든 포지션들이다:
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 369% 증가</li>
</ul>
<ul>
<li>마이크로스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) 200% 증가</li>
</ul>
<ul>
<li>코메딕스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) 85% 증가</li>
</ul>
<ul>
<li>HDFC 은행 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) 6% 증가</li>
</ul>
다음은 엘리엇이 4분기에 청산한 모든 포지션들이다:
<ul>
<li>캐털렌트 (CTLC)</li>
</ul>
<ul>
<li>카디널 헬스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
</ul>
<ul>
<li>유니티 소프트웨어 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>)</li>
</ul>
<ul>
<li>빌 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)</li>
</ul>
엘리엇은 Arm 홀딩스, 아메리칸 항공 및 알래스카 에어 그룹 등의 여러 종목에서 콜 옵션을 청산했다. 또한 에퀴닉스, 하얏트 호텔 및 호스트 호텔 등의 여러 풋 포지션도 청산했다.
다음은 엘리엇이 4분기에 축소한 모든 포지션들이다:
<ul>
<li>아이콘 Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) 62% 감소</li>
</ul>
<ul>
<li>링센트럴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RING#NYSE">RING</a>) 55% 감소</li>
</ul>
<ul>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) 50% 감소</li>
</ul>
<ul>
<li>컨플루언트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) 37% 감소</li>
</ul>
<ul>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) 2% 감소</li>
</ul>
위 정보에는 분기 동안 추가되거나 축소된 콜 또는 풋 옵션이 포함되어 있지 않다.
이 정보는 <a href="https://13f.info/13f/000101359425000294/compare/000101359424000968" target="_blank" rel="noreferrer noopener">13f.info</a> 의 비교 도구를 사용하여 수집되었습니다.
다음 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/4%EB%B6%84%EA%B8%B0%EC%97%90-%ED%97%A4%EC%A7%80%ED%8E%80%EB%93%9C%EA%B0%80-%EA%B8%8D%EC%A0%95%EC%A0%81%EC%9C%BC%EB%A1%9C-%ED%8F%89%EA%B0%80%ED%95%9C-%EC%83%81%EC%9C%84-5%EA%B0%9C-%EA%B8%B0%EC%88%A0/" target="_blank" rel="noopener">4분기 헤지펀드가 긍정적으로 평가한 5대 기술주 (힌트: NVIDIA가 아닙니다)</a></li>
</ul>
이 그림은 Midjourney를 통해 인공지능으로 생성되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

겉보기에는 결제 처리 전문 회사인 빌 홀딩스(빌닷컴)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)이 지난주처럼 폭락할 이유가 없어 보였다. 목요일, 이 회사는 <a href="https://www.benzinga.com/news/earnings/25/02/43547695/bill-holdings-stock-plunges-on-q2-earnings-whats-going-on">2023 회계년도 2분기 재무 결과</a>를 발표하며 3억 6,255만 달러의 매출과 주당 56센트의 조정된 순이익을 기록했다. 이 수치는 각각 3억 6,023만 달러와 46센트라는 애널리스트들의 컨센서스 예상치를 모두 초과한 결과이다. 그럼에도 불구하고 빌닷컴의 주식은 실적 결과 발표 후 급락했다.
심지어 특정 요소를 분석하더라도, 이 결제 처리 회사가 왜 하락했는지에 대한 전반적인 맥락을 모르는 사람에게는 쉽게 이해가 되지 않았다. 예를 들어, 전체 매출은 전년 대비 14% 증가했고, 핵심 매출(구독 및 거래 수수료로 구성됨)은 16% 상승했다. 게다가 빌닷컴은 분기를 마무리할 때 15억 7천만 달러의 현금 및 현금성 자산을 보유하고 있었다.
이 결과를 흥미롭게 분석한 경영진은 &#8220;중소기업을 지원하는 것&#8221;을 목표로 하고 있다고 언급했으며, 이는 빌닷컴의 주요 사업 분야에 해당한다. 가장 중요한 점은 이 회사가 연간 매출 전망을 14억 5천만 달러에서 14억 7천만 달러로 상향 조정한 것이다. 이 가이던스는 이전 예상인 14억 6천만 달러에 비해 긍정적으로 작용했다.
이러한 수치들이 훌륭하게 보였음에도 불구하고 빌닷컴의 주식은 금요일에 폭락했다. 이는 명백한 질문을 제기한다. &#8220;왜?&#8221; 키뱅크(KeyBanc)의 애널리스트 알렉스 마크그라프(Alex Markgraff)가 이 상황을 잘 요약했듯이, 그의 <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43568285/bills-post-earnings-selloff-analysts-weigh-fx-headwinds-take-rate-woes">성장 예상이 잘못됐다</a>고 하면서 빌닷컴은 자본이 증발한 것을 정당화한다고 언급했다. 다른 애널리스트들은 3분기 가이던스가 평범하게 나타났고, 혁신적이지 않았다고 언급했다.
일반적으로 2분기 실적은 좋았지만, 매출 성장 둔화에 대한 우려가 커지기 시작했다. 또한 빌닷컴이 중소기업들(SMB)에 노출되어 있다는 점은 투자자들을 불안하게 만들 수 있으며, 이는 <a href="https://www.benzinga.com/news/24/12/42735416/el-erian-warns-of-hidden-crisis-in-exceptional-us-economy-as-lower-income-households-face-considerable-challenges">경제적 어려움</a>에 대한 우려와 맞물릴 수 있다.
또한 읽기: <a href="https://www.benzinga.com/news/global/25/02/43604572/jd-vance-quarterbacking-tiktok-deal-will-his-venture-capital-experience-secure-a-win">JD 밴스, 틱톡 거래의 쿼터백: 그의 벤처 캐피탈 경험이 승리를 보장할까?</a>
<h2 class="wp-block-heading">빌닷컴 주식은 매력적인 가치 제안을 제공</h2>
이러한 전반적인 맥락을 고려할 때, 빌닷컴의 주식이 주가 하락을 겪어야 했느냐는 질문보다 하락폭의 크기가 문제이다. 매도세 발생 전, 빌닷컴은 100달러 선에서 거래되었다. 현재 작성 시점에서 주가는 약 65달러이다. 이 폭락은 가치 탐색자들을 흥분하게 만들고 있다.
현재 빌닷컴 주식의 주가 수익 비율은 <a href="https://finance.yahoo.com/quote/BILL/key-statistics/">159배 이상</a>이다. 그러나 향후 기준으로, 빌닷컴은 순이익 37배 미만으로 거래되고 있다. 또한 매출이 가이던스 중간값인 14억 6천만 달러에 도달할 경우, 주식은 예상 매출의 4.63배에 불과하다. 작년 첫 분기 동안 매출 배수는 평균 6.13배였다.
경제적 우려가 남아있고, 빌닷컴의 SMB 노출이 위험 요소가 될 수 있지만, <a href="https://www.benzinga.com/news/econ-s/25/02/43565669/january-jobs-report-not-too-hot-not-too-cold-leaves-interest-rate-cuts-unlikely-expert">1월 고용 보고서</a>가 기술적으로 예상보다 낮게 나왔음에도 불구하고, 12월 전체 고용 성장률이 <a href="https://www.benzinga.com/news/25/01/42934513/job-growth-fed-jitters-and-rising-mortgage-rates-this-week-in-economics">비정상적으로 강하게 나타났다</a>는 점을 지적하는 것도 공정하다. 데이터 내의 소음 속에서 일부 애널리스트들은 노동 시장이 안정적인 상태에 있다고 주장한다.
그럼에도 불구하고 가장 설득력 있는 주장은 빌닷컴 주식의 통계적 데이터를 사용하는 것이다. 지난 5년의 데이터를 사용하면, 빌닷컴은 상승 편향을 보인다. 주 초에 매수한 포지션이 주말까지 상승할 확률은 52.12%이다. 4주 기간으로 늘리면, 그 확률은 54.47%로 증가한다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-775184" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-1024x576.jpg" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10143450/BILL-stock-probability-gambit.jpg 1280w" alt="" width="1024" height="576" /><figcaption class="wp-element-caption">작성자 제공 이미지</figcaption></figure>
더욱 매력적인 점은 단순한 확률적 또는 시간적 프레임워크로 데이터를 보는 대신, 데이터를 동적인 관점에서 필터링할 수 있다는 것이다. 지난주, 빌닷컴의 주식은 33.83% 하락했다. 이는 극단적인 두려움의 이벤트라고 할 수 있다. 빌닷컴이 한 주에 10% 이상 하락한 경우(지난 5년 동안)에는, 일주일 후 다시 상승할 확률이 60.71%이다. 4주 후로 늘리면, 그 확률은 78.57%로 상승한다.
<h2 class="wp-block-heading">강세 옵션 거래 전략</h2>
높은 상승 확률에 대한 중요한 경고는 긍정적인 시나리오에서의 중간 수익률이 그리 특별하지 않다는 점이다. 극단적인 두려움의 사건(한 주에 10% 이상 하락한 경우) 이후 4주 후의 중간 수익률은 8.34%이다. 이는 금요일 종가 기준으로 67.31달러에 해당하며, 이는 69.24달러라는 목표보다 낮은 수치이다. 후자는 확률적 프레임워크를 사용하여 계산된 것이다.
너무 깊이 들어가지 않고, 시장 조성자들이 빌닷컴 주식의 반등을 예상하고 있다는 점을 고려할 때, 콜 옵션은 아마도 정상보다 높은 프리미엄으로 가격이 책정될 것이다. 이러한 상황 때문에, 더 좁은 <a href="https://www.benzinga.com/money/bull-spread">불 콜 스프레드</a>를 고려하는 것이 더 나을 수 있다. 이 접근 방식은 전체 스프레드가 완전히 무가치하게 만료될 위험을 크게 증가시키지만, 더 넓고 더 &#8220;보호적인&#8221; 스프레드를 위한 순부채가 부담스러울 수 있다.
이 점을 염두에 두고 고려할 아이디어는 64/67 불 콜 스프레드(64달러 콜 매수, 67달러 콜 매도)를 3월 7일 만기 옵션 체인에 적용하는 것이다. 빌닷컴의 주식이 만기 때 67달러를 초과할 가능성이 높기 때문에, 숏 콜 행사 가격이 최대 수익을 얻을 확률을 높여준다(작성 시점에서 약 87%이다).
또한 64달러 롱 콜은 강세 시나리오가 완전히 실현되지 않을 경우 회수 가능한 가치의 기회를 제공한다. 사용 가능한 콜 스프레드 중에서 64/67 스프레드는 현재 상황에 비추어 볼 때 가장 합리적인 스프레드 중 하나일 수 있다.
주가 움직임: 빌닷컴의 주식은 월요일 4.57% 상승한 64.97달러에 마감되었다.
다음 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43605038/coca-cola-stock-is-bubbling-higher-can-q4-earnings-keep-the-fizz-going">코카콜라 주식이 상승하고 있다: 4분기 실적이 상승세를 유지할 수 있을까?</a></li>
</ul>
사진: Ground Picture/Shutterstock.com
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

빌 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)는 목요일(6일) 2분기 재무 실적을 발표한 후 주가가 시간외 거래에서 급락했다. <a href="https://www.benzinga.com/pressreleases/25/02/b43544675/bill-reports-second-quarter-fiscal-year-2025-financial-results">실적 보고서 요약은 다음과 같다.</a>
<ul>
<li>2분기 매출: 3억 6,255만 달러, <a href="https://www.benzinga.com/calendars/earnings">예상치</a> 3억 6,023만 달러 상회</li>
<li>2분기 조정 주당순이익: 56센트, 예상치 46센트 상회</li>
</ul>
총 매출은 전년 대비 14% 증가했고, 구독료와 거래 수수료로 구성된 핵심 매출은 16% 증가했다. 분기 말에 현금 및 현금 등가물로 15억 7천만 달러를 보유하고 있었다.
빌 홀딩스의 설립자이자 CEO인 르네 라세르테는 "우리는 중소기업을 위한 사실상 지능형 재무 운영 플랫폼이라는 비전을 실현하면서 강력한 재무 성과를 달성하고 빠른 속도로 혁신을 이루었다&#8221;고 말했다.
"우리는 리더십의 위치를 활용하여 중소기업과 파트너들에게 힘을 실어주고 있으며, 플랫폼의 깊이와 폭, 그리고 다양한 유통 생태계를 확장함으로써 우위를 확대하고 있다. 현재 480,000개 이상의 기업이 BILL을 통해 일상적인 재무 워크플로를 관리한다. 우리는 수백만 중소기업의 재무 운영을 혁신할 수 있는 거대한 시장 기회를 잡기 위해 빠르게 움직인다.&#8221;
가이던스: 빌 홀딩스는 3분기 매출이 3억 5,250만~3억 5,750만 달러로 추정되며, 이는 3억 6,036만 달러의 예상치보다 낮은 수준이다. <a href="http://pro.benzinga.com/">Benzinga Pro</a>에 따르면, 3분기 조정 주당순이익은 34~38센트 사이로 추정되며, 이는 34센트의 예상치보다 높다.
또한 빌 홀딩스는 연간 전망치를 상향 조정했다. 연간 매출이 14억 5천만~14억 7천만 달러에 이를 것으로 예상했는데, 이는 추정치 14억 6천만 달러보다 높은 수치다. 연간 조정 주당순이익은 1.87~1.97달러 사이가 될 것으로 예상하고 있다.
BILL 주가 움직임: 빌 홀딩스 주식은 목요일 29.11% 하락한 68.30달러에 거래되고 있다.
이미지: Midjourney 통해 인공지능으로 생성
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 <a href="https://www.benzinga.com/news/24/10/41417317/southwest-airlines-in-settlement-talks-with-activist-investor-elliott-management-to-avoid-proxy-figh">여행 및 숙박</a>에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.
여기 3분기에 엘리엇이 새로 취득한 모든 포지션이 있다:
<ul>
<li>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</li>
</ul>
<ul>
<li>Arm 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) 콜 옵션</li>
</ul>
<ul>
<li>텍사스 인스트루먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) 콜 옵션</li>
</ul>
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 콜 옵션</li>
</ul>
<ul>
<li>Energy Select Sector SPDR Fund Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) 콜 옵션</li>
</ul>
<ul>
<li>알래스카 에어 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) 콜 옵션</li>
</ul>
<ul>
<li>아메리칸 항공 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이콘 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이큐비아 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) 콜 옵션</li>
</ul>
<ul>
<li>메리어트 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) 풋 옵션</li>
</ul>
<ul>
<li>힐튼 월드와이드 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) 풋 옵션</li>
</ul>
<ul>
<li>에퀴닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NASDAQ">EQX</a>) 풋 옵션</li>
</ul>
<ul>
<li>하얏트 호텔 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) 풋 옵션</li>
</ul>
<ul>
<li>Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) 풋 옵션</li>
</ul>
3분기 동안 엘리엇이 늘린 모든 포지션을 살펴보겠다:
<ul>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) 919% 증가</li>
</ul>
<ul>
<li>웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) 90% 증가</li>
</ul>
<ul>
<li>엣시 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) 11% 증가</li>
</ul>
<ul>
<li>매치 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) 3% 증가</li>
</ul>
이번 분기에 엘리엇이 줄인 모든 포지션은 다음과 같다:
<ul>
<li>빌 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) 24% 감소</li>
</ul>
<ul>
<li>블랙라인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) 20% 감소</li>
</ul>
<ul>
<li>씨드릴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) 9% 감소</li>
</ul>
<ul>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) 7% 감소</li>
</ul>
위의 정보는 분기 동안 증가하거나 줄어들거나 완전히 매도된 콜 또는 풋 옵션을 포함하지 않았다.
이 정보는 <a href="https://13f.info/13f/000101359424000968/compare/000101359424000660">13f.info</a>의 비교 도구를 사용하여 수집되었습니다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/hedge-funds/24/11/41995340/nelson-peltzs-trian-fund-management-reshaped-portfolio-ahead-of-presidential-election">넬슨 펠츠의 트라이언 펀드 매니지먼트가 대선 전 포트폴리오를 재편성</a></li>
</ul>
사진: Pixabay.

ETSY

MTCH

SDRL

엘리엇이 3분기에 웨스턴 디지털, 엣시는 추가; 씨드릴, 블랙라인, NRG 에너지는 축소

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
1. 셈테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>)의 주식은 회사가 예상보다 나은 <a href="https://www.benzinga.com//node/40587744" target="_blank" rel="noreferrer noopener">2분기 재무 결과</a>를 발표한 후 19.43% 급등했다. 몇몇 애널리스트들은 <a href="https://www.benzinga.com/quote/SMTC/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
2. 스테바나토 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>)의 주식은 지난주에 17.89% 상승했다.
3. 암바렐라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>)의 주식은 회사가 예상보다 나은 <a href="https://www.benzinga.com//node/40602443" target="_blank" rel="noreferrer noopener">2분기 결과</a>를 발표한 후 17.29% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/amba/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
4. 아던트 헬스 파트너스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>)의 주식은 15.16% 상승했다.
5. 빌 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)의 주식은 회사의 CEO와 CFO가 주식 매입을 공개한 후 13.98% 상승했다.
6. 박스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>)의 주식은 회사가 예상보다 나은 <a href="https://www.benzinga.com//node/40588205" target="_blank" rel="noreferrer noopener">2분기 결과</a>를 발표하고 3분기 및 <a href="https://www.benzinga.com//node/40588205" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스</a>를 예상보다 높게 발표한 후 12.88% 상승했다. 몇몇 애널리스트들은 <a href="https://www.benzinga.com/quote/box/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
7. 그루포 피난시에로 갈리시아 S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGAL#NASDAQ">GGAL</a>)의 주식은 JP모건이 주식을 비중 축소에서 비중 확대으로 상향 조정하고 <a href="https://www.benzinga.com/quote/ggal/analyst-ratings" target="_blank" rel="noreferrer noopener">54달러의 목표 주가를 발표</a>한 후 11.91% 상승했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%ac%eb%9f%ac-%ec%a0%9c%eb%84%88%eb%9f%b4-%eb%b0%8f-%ed%85%8c%eb%ac%b4%ec%9d%98-%eb%aa%a8%ed%9a%8c%ec%82%ac-pdd%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc/" target="_blank" rel="noopener">달러 제너럴 및 PDD는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 25일-8월 31일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%eb%b0%8f-%eb%aa%bd%ea%b3%a0db%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10%ea%b0%9c-%eb%8c%80%ed%98%95/" target="_blank" rel="noopener">어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)</a></li>
</ul>
사진 제공: Sundry Photography via Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Mid Cap

AMBA

ARDT

GGAL

SMTC

STVN

암바렐라 및 빌 홀딩스는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (8월 25일-8월 31일)

Comments

BILL Holdings

뉴스

에 대한 최신 뉴스 BILL Holdings (NYSE:BILL) 주식

목요일, 2월 20, 2025

화요일, 2월 11, 2025

금요일, 2월 07, 2025

금요일, 11월 15, 2024

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌